New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 15, 2012
06:02 EDTXOM, CVX, CVI, BP, TSO, RDS.AU.S. oil production surges but consumers paying more, WSJ reports
Soaring U.S. oil production is pushing down domestic benchmark crude prices and delivering a windfall to some refiners and their investors. But it's not helping consumers at the pump, reports the Wall Street Journal. U.S. crude production is expected to rise 12% this year and 8% in 2013, when it will hit the highest level since 1993, according to government figures. The price of West Texas crude, the U.S. benchmark, has fallen 7% this year, held down by rising supplies from new drilling methods. Still, gasoline prices currently average nearly $4 per gallon nationwide. Reference Link
News For A;BP;XOM;TSO;CVI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
17:04 EDTBPBP to pay Transocean $125M in compensation for legal fees
Subscribe for More Information
17:03 EDTBPTransocean reaches settlement agreements with BP, PSC
Subscribe for More Information
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
15:01 EDTBPHalliburton reaches agreement with BP to resolve remaining issues
Subscribe for More Information
13:15 EDTXOMExxon Mobil announces significant oil discovery offshore Guyana
Exxon Mobil announced a significant oil discovery on the Stabroek Block, located approximately 120 miles offshore Guyana. The well was drilled by ExxonMobil affiliate, Esso Exploration and Production Guyana Ltd., and encountered more than 295 feet of high-quality oil-bearing sandstone reservoirs. It was safely drilled to 17,825 feet in 5,719 feet of water. Stabroek Block is 6.6M acres. The well was spud on March 5. The well data will be analyzed in the coming months to better determine the full resource potential. Esso Exploration and Production Guyana Ltd. holds 45% interest. Hess Guyana Exploration Limited holds 30% interest and CNOOC Nexen Petroleum Guyana Limited holds 25% interest.
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:01 EDTBPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:12 EDTBPBP downgraded to Sell from Neutral at Goldman
Goldman downgraded BP to Sell based on limited upstream growth, a slowdown in asset disposals, and ongoing overhang from Macondo.
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:44 EDTXOM, BPEnvironmentalists file lawsuit over oil train safety rules, NY Times says
Subscribe for More Information
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 12, 2015
05:38 EDTBPTechnip awarded lump sum project by BP Exploration & Production
Subscribe for More Information
May 11, 2015
13:28 EDTBP, XOMOPEC sees oil at around $76 a barrel in 2025, WSJ says
Subscribe for More Information
10:01 EDTXOMExxon Mobil announces Cold Lake project expansion begins production on schedule
Subscribe for More Information
May 8, 2015
18:09 EDTBPCourt says BP can appeal some Gulf spill damages claims, Reuters reports
A U.S. federal appeals court said BP should be allowed to appeal some damage claims awarded to those in connection with the 2010 Gulf of Mexico oil spill, Reuters reports. The decision by the 5th U.S. Circuit Court of Appeals in New Orleans may help BP limit its payout to victims of the Deepwater Horizon drilling rig explosion, Reuters added. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use